<DOC>
	<DOCNO>NCT00346697</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety omega-3-fatty acid HIV-infected patient hypertriglyceridemia . In addition , , researcher , evaluate effect omega-3 fatty acid administration marker bone turnover inflammation .</brief_summary>
	<brief_title>Omega-3 Fatty Acids High Triglycerides HIV-infected Patients</brief_title>
	<detailed_description>Hypertriglyceridemia common among HIV-infected patient receive Highly Active Antiretroviral Therapy ( HAART ) . Although fibrates , statin , niacin use management hypertriglyceridemia HIV-infected patient , optimal control difficult achieve agent need . Omega-3 fatty acid effective lower triglyceride patient without HIV infection , experience HIV-infected patient limited . In addition , omega-3 fatty acid may also secondary benefit decrease bone resorption decrease marker systemic inflammation . The purpose study evaluate efficacy safety omega-3-fatty acid HIV-infected patient hypertriglyceridemia . In addition , evaluate effect omega-3 fatty acid administration marker bone turnover inflammation . It 8- week randomize , double-blind trial omega-3 fatty acid ( LOVAZA , GSK , Inc ) compare placebo 48 HAART-treated HIV-infected patient triglyceride 250 1000 mg/dl receive dietary counseling . Subjects recruit three center ( Johns Hopkins , Georgetown , Los Angeles VAMC ) . The primary endpoint change triglyceride concentration baseline LOVAZA group compare placebo group . Secondary endpoint include effect LOVAZA lipid target ( total cholesterol , LDL cholesterol , HDL-cholesterol ) , marker systemic inflammation , marker bone turnover , marker insulin resistance , HIV-disease control ( CD4+ count , HIV viral load ) , measure hepatotoxicity ( ALT ) , platelet function , patient report adverse event . Omega-3 fatty acid may useful adjunct treatment hypertriglyceridemia HIV-infected patient , additional control study need assess safety efficacy use purify , standardized preparation .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<criteria>Ability willingness give inform consent Age â‰¥ 18 year HIV1 infection document time prior study entry Fasting plasma triglyceride value 200 1000 mg/dL two occasion within 4 week Subjects must receive stable antiretroviral medication regimen &gt; 3 month without anticipate change study interval Females must pregnant lactating . Females childbearing potential male must use reliable mean contraception On stable lipid modification pharmacotherapy least 8 week prior study entry Exclusion Criteria Hemoglobin A1C &gt; 8.5 % Uncontrolled hypothyroidism ( TSH &gt; 4.5 ) HIV viral load &gt; 5,000 copies/ml ( cpm ) , Active liver disease and/or liver transaminases great 2.0 X upper limit normal Active kidney disease serum creatinine &gt; 2.5 mg/dL Myocardial infarction , unstable ischemic heart disease , stroke , coronary revascularization procedure Uncontrolled hypertension within 4 week study entry ( SBP &gt; 180 mmHg DBP &gt; 100 mmHg ) Use systemic cancer chemotherapy within 8 week study entry Pregnancy breastfeed Drug alcohol dependence , condition may affect study compliance History coagulopathy use anticoagulant warfarin Use omega3 fatty acid preparation 12 week prior randomization Significant change clinical status Screening Visit would preclude patient appropriate candidate . Any following laboratory parameter : hematocrit &lt; 25 % , absolute neutrophil count &lt; 1.5 x 10^9/L , platelet &lt; 100 x 10^9/L hemoglobin &lt; 8.0 gm/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>AIDS</keyword>
	<keyword>HIV</keyword>
	<keyword>HAART</keyword>
	<keyword>Lipids</keyword>
	<keyword>Triglycerides</keyword>
	<keyword>Cholesterol</keyword>
	<keyword>omega-3 fatty acid</keyword>
	<keyword>bone turnover</keyword>
	<keyword>inflammation</keyword>
	<keyword>insulin resistance</keyword>
</DOC>